Disc Medicine's (IRON) "Outperform" Rating Reiterated at Wedbush

Key Points

• Wedbush reaffirmed its “outperform” rating on Disc Medicine and set a $100 price target, implying 30.7% upside from the prior close. Analysts’ consensus is “Moderate Buy,” with an average target of $109.55.
• Disc Medicine reported quarterly EPS of -$1.54, beating the consensus estimate of -$1.71; analysts expect a full-year loss of approximately $6.61 per share.
• Insiders sold 209,797 shares worth about $15.9 million over the past 90 days, while institutional investors own a substantial 83.7% of the company.

Disc Medicine (NASDAQ:IRON - Get Free Report)'s stock had its "outperform" rating reaffirmed by equities research analysts at Wedbush in a research report issued on Thursday, Benzinga reports. They presently have a $100.00 price target on the stock. Wedbush's target price would suggest a potential upside of 30.70% from the stock's previous close.

Several other equities research analysts also recently commented on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Disc Medicine in a research note on Tuesday, September 1st. Jefferies Financial Group reiterated a "buy" rating and set a $128.00 target price on shares of Disc Medicine in a research report on Thursday. Morgan Stanley reissued an "overweight" rating and set a $90.00 price target on shares of Disc Medicine in a report on Monday, August 17th. BMO Capital Markets restated an "outperform" rating on shares of Disc Medicine in a research report on Thursday. Finally, Wall Street Zen cut shares of Disc Medicine from a "hold" rating to a "sell" rating in a research note on Saturday, August 29th. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Disc Medicine has a consensus rating of "Moderate Buy" and an average price target of $109.55.

Disc Medicine Price Performance

Shares of IRON stock opened at $76.51 on Thursday. The stock's fifty day simple moving average is $77.96 and its 200 day simple moving average is $70.76. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14. The firm has a market cap of $293.03 million, a price-to-earnings ratio of -11.63 and a beta of 0.97. Disc Medicine has a one year low of $40.00 and a one year high of $99.50.

Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, beating analysts' consensus estimates of ($1.71) by $0.17. On average, analysts expect that Disc Medicine will post -6.61 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO John D. Quisel sold 33,000 shares of Disc Medicine stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $79.15, for a total value of $2,611,950.00. Following the completion of the transaction, the chief executive officer directly owned 226,064 shares of the company's stock, valued at $17,892,965.60. The trade was a 12.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Rahul Khara sold 5,000 shares of the company's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $80.00, for a total transaction of $400,000.00. Following the transaction, the insider owned 52,324 shares in the company, valued at approximately $4,185,920. This trade represents a 8.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 209,797 shares of company stock worth $15,934,791 over the last ninety days. Company insiders own 3.76% of the company's stock.

Institutional Investors Weigh In On Disc Medicine

A number of hedge funds have recently added to or reduced their stakes in IRON. Arizona State Retirement System raised its stake in shares of Disc Medicine by 2.4% in the second quarter. Arizona State Retirement System now owns 6,844 shares of the company's stock worth $501,000 after acquiring an additional 160 shares during the last quarter. Police & Firemen s Retirement System of New Jersey increased its holdings in shares of Disc Medicine by 3.3% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 6,716 shares of the company's stock valued at $533,000 after purchasing an additional 215 shares in the last quarter. AlphaCentric Advisors LLC increased its holdings in shares of Disc Medicine by 5.8% in the first quarter. AlphaCentric Advisors LLC now owns 3,972 shares of the company's stock valued at $254,000 after purchasing an additional 216 shares in the last quarter. Kennedy Capital Management LLC raised its position in Disc Medicine by 3.3% in the 4th quarter. Kennedy Capital Management LLC now owns 9,324 shares of the company's stock worth $740,000 after purchasing an additional 296 shares during the last quarter. Finally, State of Wyoming acquired a new position in Disc Medicine during the 2nd quarter worth $25,000. Institutional investors own 83.70% of the company's stock.

Disc Medicine Company Profile

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.